PR84781

TOKYO and DEVENTER, Netherlands, July 15, 2020 /PRNewswire=KYODO JBN/ --

Terumo Corporation (TSE: 4543) today announced it has completed the acquisition

of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in

the development of next-generation microspheres for Selective Internal

Radiation Therapy (SIRT), a treatment for liver tumors. Under the terms of the

agreement, Terumo acquired 80.1% of the shares of Quirem Medical. This is over

and above its current share position of 19.9%, making Quirem Medical now a

wholly owned subsidiary of Terumo.

Terumo will make a one-time, up-front payment of USD 20 million with up to USD

25 million additional payments based on the achievement of future milestones by

2030. It will be funded through cash on hand and will not significantly impact

the company’s financial projections for the current fiscal year ending March

31, 2021.

Quirem Medical has developed and manufactures QuiremSpheres(TM), the only

commercially available microspheres containing the radioactive isotope

Holmium-166. Recent trials have shown the safety and efficacy of holmium

microspheres for the treatment of unresectable liver cancer. To improve patient

selection, therapy planning and treatment verification, QuiremSpheres can be

visualized and quantified even in low concentrations by means of Single-Photon

Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This

is unique and cannot be done with currently available Yttrium-90 based

microspheres.

Furthermore, Quirem Medical also produces QuiremScout(TM), a low dose holmium

microsphere that helps evaluate the biodistribution of microspheres prior to

therapy, and a dosimetry software package, Q-Suite(TM), which is used to plan

QuiremSpheres treatments based on QuiremScout dose imaging. Q-Suite is also

able to determine SIRT success immediately after the procedure by converting

SPECT and MR imaging into absorbed dose distributions. Together, these three

integrated products (QuiremSpheres, QuiremScout and Q-Suite) make up the full

Holmium SIRT Platform. The Holmium Platform equips physicians with the

necessary tools to optimize SIRT outcomes through more personalized treatment,

addressing the individual needs of each patient.

QuiremSpheres, QuiremScout and Q-Suite are CE-Marked and currently available in

Europe, the Middle East and Africa (EMEA). In the coming years, Terumo intends

to launch the Holmium Platform globally as part of the ongoing expansion of its

interventional oncology (IO) portfolio.

“The acquisition of Quirem Medical further strengthens our business, expands on

our manufacturing and clinical development activities, and complements our

comprehensive suite of offerings to support our customers,” said Jim Rushworth,

Chief Commercial Officer of the Interventional Systems Division of Terumo.

Using Quirem’s innovative Holmium-166 platform technology, physicians are

further empowered to drive treatment outcomes after SIRT. “By adding the

Holmium-166 platform to our existing IO portfolio, we will further contribute

to giving liver cancer patients a better future,” said Laurent Domas, Vice

President, Global Interventional Oncology Strategy & Therapy Development,

Terumo Europe. "This acquisition reflects Terumo's commitment to build a broad

platform of loco-regional treatment options for liver cancer and is another

step forward as we aim to develop and provide treatment solutions for other

organs as well.”

“We are very excited with the acquisition of Quirem Medical by Terumo as it

will further drive the adoption of our unique product offerings worldwide and

accelerate our pace of innovation, reaching more patients that will benefit

from our technology,” said Jan Sigger, CEO of Quirem Medical.

The global interventional oncology market value is more than USD 1 billion,

which is a rapidly growing field with a CAGR of 7%. Within this field, SIRT is

one of the main treatments that is expected to help to drive this growth year

on year.

Terumo has been building its presence in the interventional oncology field,

with product offerings such as the micro catheter system (Progreat(TM)),

compressible microspheres for embolization (HydroPearl(TM)), drug-eluting

microspheres (LifePearl(TM)), and biodegradable drug eluting microspheres

(BioPearl(TM)). In 2015, Terumo invested in Quirem Medical and became the

exclusive global distributor of their technology.

About Quirem Medical B.V.

Quirem Medical develops and commercializes the next-generation Selective

Internal Radiation Therapy (SIRT) microspheres based on the radioisotope

Holmium-166. The company believes the treatment outcome of unresectable liver

cancer with SIRT can be optimized with Holmium-166 microspheres, which can be

visualized and quantified to improve SIRT patient selection, treatment planning

and treatment verification. Its innovative Holmium-166 platform technology

provides physicians a complete CE-marked SIRT solution including

QuiremScout(TM), QuiremSpheres(TM) and the supporting dosimetry software

Q-Suite(TM). The company is based in Deventer, the Netherlands and has

approximately 30 employees.

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been

committed to "Contributing to Society through Healthcare" for nearly 100 years.

Based in Tokyo and operating globally, Terumo employs more than 25,000

associates worldwide to provide innovative medical solutions in more than 160

countries and regions. The company started as a Japanese thermometer

manufacturer and has been supporting healthcare ever since. Now, its extensive

business portfolio ranges from vascular intervention and cardio-surgical

solutions, blood transfusion and cell therapy technology, to medical products

essential for daily clinical practice. Terumo will further strive to be of

value to patients, medical professionals, and society at large.

Logo - https://mma.prnewswire.com/media/1214359/Terumo_Logo.jpg

Source: Terumo